Document:

EMPLOYMENT CONTRACT BETWEEN

                            BIOCELL INNOVATIONS, INC.
                                       AND
                                    GLEN ODOM

This Employment Contract made and entered into this seventh day of April 2002,
by and between BioCell Innovations, Inc. ("EMPLOYER"), and Glen Odom
("Vice-President") as ratified by action of the board of directors of EMPLOYER
at a regular meeting held on April 16, 2002. This contract incorporates and
replaces all prior contracts and/or amendments thereto.

EMPLOYER is Texas Corporation.

In consideration of the mutual promises of each, and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged by
both the EMPLOYER and Vice-President agree as follows:

1.     TERM:
The EMPLOYER employs the Vice-President, and the Vice-President hereby accepts
employment as a Vice-President for a TWO YEAR term commencing on April 1,2002
and ending on April 1,2004. At the end of the two-year period, this agreement
will automatically be extended for a three year period unless within 90 days
prior to the termination date either party gives notice to the other party of
its intent to cancel the agreement. If EMPLOYER gives notice of termination,
EMPLOYER shall pay to Vice-President one year's salary in order to make the
termination effective. The parties recognize that if nothing is agreed upon
otherwise, Texas is a right-to-work state allowing the employer to terminate
employment at will and without cause, and EMPLOYER expressly agrees that this
employment will not be employment at will but shall be governed exclusively by
the terms of this agreement.

2. CONDITIONS OF EMPLOYMENT

A. DUTIES
The Vice-President is to be the Chief Operating Officer of the EMPLOYER having
the duties normally associated with such position.

The duties of Vice-President shall include, but are not limited to the
following:

     1. Manage all of the affairs of the EMPLOYER and its personnel. Such duties
may be delegated to other employees providing, however, that the Vice-President
is responsible for the decisions made by the person to whom the authority is
delegated.

     2. Implement policies established by the EMPLOYER through its governing
structure.

     3. Advise the board with respect to all operating matters.

     4. Attend all board of directors meetings.

     5. Perform such other duties as are customarily performed by a
Vice-President and such other duties as assigned by EMPLOYER that are within the
capability of Vice-President.

     6. Use his best efforts to maximize the profits of the EMPLOYER.

B. LIMITATION OF AUTHORITY
Notwithstanding other terms herein, Vice-President shall not have the right to
make contracts or commitments unless authorized by the Board of Directors of the
EMPLOYER.

C. SUPERVISION OF VICE-PRESIDENT
Vice-President reports to the President of the EMPLOYER.

D. REVIEW OF DOCUMENTS
The EMPLOYER, individually and collectively, shall refer all business documents
and decisions to Vice-President for review and comment.

<PAGE>

E. BOARD/MANAGEMENT MEETINGS
The Vice-President shall attend appropriate meetings of the owner, board of
directors, with the exception of executive sessions devoted to the consideration
of any action or lack of action on the Vice-President's contract, the
Vice-President's salary or benefits, or the Vice-President's evaluation.

F. PROFESSIONAL ORGANIZATIONS, MEETINGS AND ACTIVITIES
The Vice-President shall devote his time, attention, and energy to the
coordination of the legal affairs of the corporation. The Vice-President shall
attend and participate in appropriate professional meetings at the local, state,
and national levels with the reasonable expenses for such attendance to be borne
by the EMPLOYER, including membership fees and dues of the Vice-President in
such organizations as he deems appropriate in the performance of his duties. The
Vice-President may hold offices or accept responsibilities in these professional
organizations, provided that such responsibilities do not interfere with the
performance of his duties as Vice-President.

G. OUTSIDE ACTIVITIES
The Vice-President shall be allowed to reasonably disengage from his present
employment. The Vice-President shall (on his own time and not company time
unless approved by the Vice-President) be allowed to publish articles and books
and give lectures and speeches.

H. LIMITATION TO CONSULTATION ACTIVITIES/OUTSIDE EMPLOYMENT
Notwithstanding paragraph 2G, Vice-President shall not, without the express
written consent of EMPLOYER, be interested directly or indirectly, in any
manner, as a partner, officer, director, shareholder, adviser, employee, or in
any other capacity in any other business similar to EMPLOYER's business or any
allied trade; provided, however, that nothing contained in this section shall be
deemed to prevent or to limit the right of Vice-President to invest any of his
money in the capital stock or other securities of any corporation whose stock or
securities are publicly owned or are regularly traded on any public exchange,
nor shall anything contained in this section be deemed to prevent Vice-President
from investing or limit Vice-President's right to invest his or her money in
real estate.

                               I. CIVIC ACTIVITIES
The Vice-President is encouraged to participate in community and civic affairs.
The membership and direct expenses of such memberships and activities shall be
paid by the EMPLOYER as permitted by law and approved by the EMPLOYER.

                     J. REASSIGNMENT AND PLACE OF EMPLOYMENT
The Vice-President shall not be reassigned from the position of Vice-President
to another position without the Vice-President's written consent. Vice-President
shall perform his duties in Harris County, Texas or a county adjacent thereto
unless he agrees otherwise.

3.  COMPENSATION
A. SALARY
EMPLOYER shall pay to Vice-President in exchange for services rendered under
this Agreement, compensation at the rate of one hundred twenty thousand Dollars
($120,000.00) per year, payable two time(s) a month on or before the first and
fifteenth days of each month while this Agreement shall be in force. This
agreement shall not go into force until EMPLOYER receives from all source an
aggregate total cash receipt in the amount of $5,000,000. At such time as the
total amount of $5,000,000 is received by EMPLOYER, Vice-President's salary
shall be increased to $150,000 per year and Vice-President shall be paid his
deferred salary. On the each anniversary of employment under this agreement,
Vice-President shall receive a salary increase of no less than 10% as decided by
the Compensation Committee of the EMPLOYER.

<PAGE>

B. HOLIDAYS
The EMPLOYER shall allow Vice-President to have as holidays all holidays that
the federal government gives to its employees.

C. VACATION AND SICK LEAVE
If Vice-President so elects, he may take 2 weeks vacation during the first 6
months of this contract and 3 weeks vacation each year thereafter.
Vice-President shall be allowed 10 sick days per year. Vice-President shall be
allowed to accrue three years of vacation and sick leave. Upon termination of
this agreement or the employment hereunder, Vice-President shall be paid on a
pro rata daily basis for any accrued vacation or sick leave.

B. REIMBURSEMENTS AND EXPENSES
EMPLOYER shall reimburse Vice-President for all reasonable expenses incurred in
travel for EMPLOYER, attending the annual conference of his professional
association, educational courses, and meetings of the local chapter of his
professional association upon presentation of appropriate expense reports. No
such expenses shall be approved unless Vice-President has prior written approval
to make such expenses.

C. LIFE INSURANCE PREMIUM
EMPLOYER shall pay Vice-President's premium on a life insurance policy as may be
later mutually agreed upon by the parties.

D. AUTOMOBILE EXPENSE.
Vice-President shall provided a vehicle of a value not to exceed $80,000 of
Vice-President's choosing, subject to the approval of the EMPLOYER. Said vehicle
shall be replaced every four years. Vice-President may use this vehicle for
business and personal purposes. EMPLOYER shall maintain automobile liability,
property damage, and comprehensive insurance and pay the normal and necessary
expenses for operation and maintenance of such vehicle.

E. MEDICAL AND DENTAL INSURANCE
EMPLOYER shall provide to Vice-President and pay the full premium for a
comprehensive family health insurance Policy for Vice-President, his spouse and
children.

4. ANNUAL PERFORMANCE EVALUATION
EMPLOYER shall evaluate and assess the performance of the Vice-President at
least yearly.

5. TERMINATION
This employment contract may be terminated by:

     A. Mutual agreement of the parties.

     B. Disability of Vice-President. If the Vice-President is permanently
disabled or is otherwise unable to perform his duties because of sickness,
accident, injury, or mental incapacity for a period of ninety (90) working days
beyond any accrued sick leave, the EMPLOYER shall have the option to terminate
this agreement.

<PAGE>

     C. Discharge for cause. In the event Vice-President commits a material
breach of the obligations and duties of Vice-President under this Agreement or
commits any acts designated as conduct violation or for just cause shall be
considered cause for immediate dismissal. EMPLOYER may terminate this Agreement,
during its term, only for "cause" which, for purposes herein, shall mean
Vice-President's (i) material and continuing failure to perform his essential
duties hereunder. Vice-President may terminate this Agreement upon any material
breach by EMPLOYER that is not cured within 30days of written notice by
Vice-President.

     D. Unilateral termination by EMPLOYER. In the event the EMPLOYER terminates
Vice-President and during such time the Vice-President is willing and able to
perform his duties under this agreement, then in that event the EMPLOYER agrees
to pay Vice-President, as severance pay, the remainder of the salary under the
contract plus one years salary.

     E. Death of Vice-President. This agreement shall terminate on the death of
Vice-President.

6. CONFIDENTIAL INFORMATION.
     (1) Definition of Confidential Information. Vice-President acknowledges
that he has been informed that it is the policy of the Employer to maintain as
secret and confidential all information relating to the following ("Confidential
Information"):

(a) The financial condition of the Employer.

(b) The systems, products, services, discoveries, designs, inventions, pricing
and bidding methods, proprietary marketing and proprietary sales techniques,
technical processes, information about costs, profits, key personnel, heretofore
or hereafter acquired, developed and/or used by the Employer other than those
that have been made generally available.

(c) The customers, prospective customers (whom Employer has contacted, made
sales presentations, provided bids, or otherwise specifically solicited during
the Term hereof), suppliers, vendors and Vice-Presidents of the Employer,
records of transactions, and other information concerning the Business of
Employer.

(d) Research records, technical data, production and processing techniques,
manufacturing processes, and the like.

The above items shall be included within the scope of Confidential Data whether
prepared by Vice-President or coming into Vice-President's possession during the
employment hereunder.

     (2) Vice-President Shall Receive Confidential Information.

     Vice-President acknowledges that Vice-President will be provided with
information about the Employer, and that the Employment during the Term hereof,
including any renewals or extensions, will continue to bring Vice-President into
close contact with confidential affairs of the Employer. Thus, Vice-President
acknowledges that by reason of Vice-President's employment by the Employer,
Vice-President will acquire Confidential Information.

<PAGE>

     (3) Vice-President Acknowledges Importance of Confidential Information.

     Vice-President acknowledges that all Confidential Information is of great
value to Employer, and essential to Employer's preservation of the Business and
the goodwill of Employer.

     (4) Vice-President's Services Special and Unique.

     The Vice-President recognizes the duties and services to be performed by
Vice-President, as a Vice-President of the Employer, are special, unusual,
extraordinary and unique, and intellectual in nature.

     (5) Vice-President Shall Not Disclose Confidential Information.

     Vice-President confirms that protection of the Employer's goodwill
reasonably necessary and that Vice-President agrees that Vice-President shall
not, directly or indirectly, except where authorized by the Board of Directors
of the Employer for the benefit of the Employer:

(a) At any time, divulge to any persons, firms, corporations, governmental
entities or agencies or other entities, other than the Employer or its
affiliates ("Third Parties"), or use or cause or authorize any Third Parties to
use, any such Confidential Information, or any other information which he knows
or should know is regarded as confidential and valuable by the Employer (whether
or not any of the foregoing information is actually novel or unique) except as
otherwise required by law. However, the Vice-President may divulge information
relating to the financial condition of the Employer to Vice-President's attorney
or accountant solely in connection with the occurrence of a change in control,
making calculations of payments required under this Agreement, or with respect
to a Termination of this Agreement and the payment of the any amounts, if any,
in accordance with this Agreement and solely for such attorney's or accountant's
use with respect thereto. Vice-President shall provide Employer with a copy of
such information and the name of the accountant or attorney given such
information.

(b) At any time during the Covenant Period, solicit or cause or authorize
directly or indirectly to be solicited, or accept or cause or authorize directly
or indirectly to be accepted, for or on behalf of himself or Third Parties, any
Business from Third Parties who are, at any time within Two (2) years prior to
the cessation of Vice-President's employment, customers or prospects of the
company; or

(c) At any time during the Covenant Period, solicit or cause or authorize
directly or indirectly to be solicited for employment, or cause or authorize
directly or indirectly to be employed, for or on behalf of the Vice-President or
Third Parties, any person who is or was, at any time within One (1) year prior
to the cessation of employment hereunder, Vice-Presidents of the Employer.

     (6) Exceptions to Non-Disclosure of Confidential Information.

     Notwithstanding the foregoing, the restrictions contained in this provision
shall not apply to any Confidential Information or portion thereof which:

(a) At the time of disclosure by the Vice-President is generally and readily
available to the public other than by an act or omission on the part of
Vice-President; or

<PAGE>

(b) At the time of disclosure by Vice-President has been acquired from or made
available to Vice-President by a Third Party having the lawful right to disclose
such information.

(c) Vice-President is required to disclose pursuant to any state or federal law,
rule or regulation or by an applicable judgment, order or decree of any court or
government body or agency having jurisdiction over such matter. However, at
least Twenty (20) days prior written notice of such required disclosure before
such disclosure is made to enable the Employer to seek an appropriate protective
order to take such other actions as it deems necessary or appropriate.

7. NON COMPETE
The Vice-President shall not, at any times during the period hereof, and for two
years from the date of termination of this Agreement, directly or indirectly,
within a geographic area of 100 miles, engage in, or become involved in, any
competitive or similar business as that of the within Employer.

8. SAVINGS CLAUSE
If any provision, or any portion thereof, contained in this Agreement is held to
be unconstitutional, invalid, or unenforceable, the remainder of this Agreement,
or portion thereof, shall be deemed severable, shall not be affected, and shall
remain in full force and effect.

9. MODIFICATION
Any modification of this Agreement or additional obligation assumed by either
party in connection with this Agreement shall be binding only if evidenced in
writing signed by each party or an authorized representative of each party.

10. SURVIVAL
If EMPLOYER or its assets are sold or control of the corporation changes, this
agreement shall survive and pass to the new corporation or entity, except,
however, either party may elect to terminate this agreement in which case
corporation or the new corporation or entity shall pay to Vice-President the
remainder of the payments to be made for the term of this agreement plus the
first extension thereof.

11. CHOICE OF LAW
It is the intention of the parties to this Agreement that this Agreement and the
performance under this Agreement, and all suits and special proceedings under
this Agreement, be construed in accordance with and under and pursuant to the
laws of the State of Texas and that, in any action, special proceeding or other
proceeding that may be brought arising out of, in connection with, or by reason
of this Agreement, the laws of the State of Texas shall be applicable and shall
govern to the exclusion of the law of any other forum, without regard to the
jurisdiction in which any action or special proceeding may be instituted.

12. NO WAIVER
The failure of either party to this Agreement to insist upon the performance of
any of the terms and conditions of this Agreement, or the waiver of any breach
of any of the terms and conditions of this Agreement, shall not be construed as
thereafter waiving any such terms and conditions, but the same shall continue
and remain in full force and effect as if no such forbearance or waiver had
occurred.

<PAGE>

13. PARAGRAPH HEADINGS
The titles to the paragraphs of this Agreement are solely for the convenience of
the parties and shall not be used to explain, modify, simplify, or aid in the
interpretation of the provisions of this Agreement.

14. COMPLETE AGREEMENT
This Agreement contains the complete agreement concerning the employment
arrangement between the parties and shall, as of the effective date hereof,
supersede all other agreements between the parties. The parties stipulate that
neither of them has made any representation with respect to the subject matter
of this Agreement or any representation including the execution and delivery of
this Agreement except such representations as are specifically set forth in this
Agreement and each of the parties acknowledges that he or it has relied on its
own judgment in entering into this Agreement. The parties further acknowledge
that any payments or representations that may have been made by either of them
to the other prior to the date of executing this agreement are of no effect and
that neither of them has relied thereon in connection with his dealings with the
other.

15. INDEMNIFICATION
Employer shall indemnify Vice-President against any and all expenses, including
amounts paid upon judgments, counsel fees, environmental penalties and fines,
and amounts paid in settlement (before or after suit is commenced), incurred by
the Vice-President in connection with his defense or settlement of any claim,
action, suit or proceeding in which he is made a party or which may be asserted
against him by reason of his employment or the performance of duties in this
Agreement. Such indemnification shall be in addition to any other rights to
which those indemnified may be entitled under any law, bylaw agreement, or
otherwise.

In witness whereof, each party to this Agreement has caused it to be executed at
Houston, TX on the date so stated.

                                    For EMPLOYER
                                    /s/ Richard Cole, CEO

/s/_______________________________
Glen OdomLSA

SPONSORED LABORATORY STUDY AGREEMENT

     THIS Agreement is made this 15th day of May 2002, between The University of
Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030
("Institution"), a component of The University of Texas System ("System"), and
BIOCELL INNOVATIONS, INC. 915 KNOWTLON AVENUE, BAYTOWN, TEXAS, 77520,
("Sponsor"), to conduct a laboratory study and evaluation ("Study"). Institution
and Sponsor agree as follows:

                                  1.  PROTOCOL

1.1     Institution agrees to use its best efforts to conduct the Study, as an
independent contractor, in accordance with Institutional policy, applicable laws
and regulations and the Project, "The use of patented processes and procedures
as described in Appendix I for the making, using, selling, proliferating,
transferring and/or making other disposition of bone marrow cells and tissues,
and bone-marrow derived peripheral blood cells and applications thereof,
including but not limited to growth and commercialization of bone marrow blood
cell cultures, growth and transplantation of blood cells and bone marrow; and
the use of blood cells and bone marrow for commercial growth of bone
marrow-derived biological products, including but not limited to red blood
cells, white blood cells, platelets, cellular growth factors, and intercellular
communication factors, and processes for making such products. The sources of
testing and commercialization materials shall be derived from sources such as
living donor biopsies, harvested from cadaver donors, living donor biopsies,
bone marrow aspirates, peripheral blood cells and other sources. Specifically
excluded as a source of bone marrow are human embryonic, fetal or neonatal cells
and tissues." as described in Exhibit A attached hereto and incorporated herein.
The Study will be supervised by Dr. Zeev Estrov, M.D., (Principal
Investigator"), at Institution, with assistance from associates and colleagues
as required.

1.2     Sponsor agrees to engage the services of Institution to conduct the
Study and further agrees to provide at no cost to Institution the materials and
equipment for the conduct of the Study.

2. AWARD

2.1     In consideration for performance of the Study by Institution, Sponsor
shall pay Institution $Three Hundred Seventy-Five Thousand and No/100 Dollars
($375,000.00) for Study expenses and other related costs. This amount, shown by
approximate category of expense in Exhibit B attached hereto for information
only, is payable in twenty-four monthly installments in the amount of $Fifteen
Thousand Six Hundred Twenty-five and NO/100 Dollars ($15,625.00) each. The first
payment is payable within thirty (30) days of the date herein above the final
payment will be due upon completion of the study.

3. TERM

3.1     This Agreement shall continue in force until the earlier of
completion of the Study as mutually agreed upon by the parties or twenty-four
(24) months from the date set forth above; provided, however, that either party
may terminate the Agreement by giving thirty (30) days advance notice to the
other.

3.2     Upon early termination of this Agreement, Sponsor shall be liable
for all reasonable costs incurred or obligated by Institution at the time of
such termination, subject to the maximum amount specified in Article 2. Sponsor
shall pay Institution for such costs within thirty (30) days of receipt of an
invoice for same.

3.3     Upon termination of this Agreement, Institution shall return Sponsor's
materials and equipment to Sponsor.

<PAGE>

4. INDEMNIFICATION

4.1     Institution  shall, to the extent authorized under the Constitution
and laws of the State of Texas, indemnify and hold Sponsor harmless from
liability resulting from the negligent acts or omissions of Institution, its
agents or employees pertaining to the activities to be carried out pursuant to
the obligations of this Agreement; provided, however, that Institution shall not
hold Sponsor harmless from claims arising out of the negligence or willful
malfeasance of Sponsor, its officers, agents, or employees, or any person or
entity not subject to Institution's supervision or control.

4.2     Sponsor shall indemnify and hold harmless System, Institution, their
Regents, officers, agents and employees from any liability or loss resulting
from judgments or claims against them arising out of the activities to be
carried out pursuant to the obligation of this Agreement, including but not
limited to the use by Sponsor of the results of the Study; provided, however,
that the following is excluded from Sponsor's obligation to indemnify and hold
harmless:

     a. the negligent failure of Institution to comply with any applicable
governmental requirements or to adhere to the terms of the Protocol; or

     b. the negligence or willful malfeasance by a Regent, officer, agent, or
employee of Institution or System.

5. PUBLICATION AND CONFIDENTIALITY

5.1     The parties reserve the right to publish or otherwise make public the
data resulting from the Study. The party so wishing to publish or make public
shall submit any such manuscript or release to the other party for comment
thirty (30) days prior to publication or release.

5.2     Except as otherwise required by law or regulation, neither party shall
release or distribute any materials or information containing the name of the
other party or any of its employees without prior written approval by an
authorized representative of the non-releasing party, but such approval shall
not be unreasonably withheld.

5.3     Each party shall hold in confidence for three (3) years after the
termination of this Agreement any confidential information identified as
confidential and obtained from the other party during the course of this Study.
Nothing herein, however, shall prevent Institution or any other component of
System from using any information generated hereunder for ordinary research and
educational purposes of a university.

6. INTELLECTUAL PROPERTY

6.1     Title to all inventions and discoveries made by Institution resulting
from the research performed hereunder shall reside in Institution; title to all
inventions and discoveries made by Sponsor resulting from the research performed
hereunder shall reside in Sponsor; title to all inventions and discoveries made
jointly by Institution and Sponsor resulting from the research performed
hereunder shall reside jointly in Institution and Sponsor. Inventorship shall be
determined in accordance with U.S. Patent law.

6.2     After consultation with Sponsor regarding the advisability of filing
patent applications, Institution shall file appropriate United States and
foreign patent applications for wholly or jointly owned Institution inventions.
Institution will provide Sponsor, on a confidential basis, a copy of any such
application filed and any documents received or filed during prosecution thereof
and will provide Sponsor the opportunity to comment thereon. On any application
on which an employee of Sponsor is named as a co-inventor, Sponsor will
cooperate in obtaining execution of any necessary documents by its employees.

<PAGE>

6.3     Institution agrees to grant to Sponsor an exclusive, worldwide,
royalty-bearing license to make, use, or sell under any invention or discovery
owned wholly or partly by Institution and made or conceived and reduced to
practice during the term of this Agreement or within twelve (12) months
thereafter and directly resulting from the performance of the research
hereunder, with right to sublicense with accounting to University. Sponsor shall
have six (6) months from disclosure of any invention or discovery to notify
Institution of its desire to enter into such a license agreement, and a license
agreement shall be negotiated in good faith within a period not to exceed twelve
(12) months from Sponsor's notification to Institution of its desire to enter
into a license agreement, or such period of time as to which the parties shall
mutually agree.

6.4     If Sponsor and Institution fail to enter into an agreement during that
period of time, Sponsor shall have a right of first refusal with respect to any
terms generally more favorable offered by Institution to a third party for a
period of one (1) year thereafter.

6.5     In the event Sponsor elects to exercise its option to negotiate a
license in accordance with the procedures detailed above, it shall be obligated
to pay all expenses, including attorney's fees, incurred in searching prior art,
obtaining search opinions, preparing applications, filing, prosecuting,
enforcing or maintaining a patent or patent application with respect to the
licensed invention in any country in which the patent or application is filed.

7.  GENERAL

     7.1     This Agreement, including the attached Exhibit A and B, constitutes
the entire and only Agreement between the parties relating to the Study, and all
prior negotiations, representations, agreements, and understandings are
superseded hereby. No agreements altering or supplementing the terms hereof,
including the exhibits attached hereto, may be made except by a written document
signed by the duly authorized representatives of the parties.

7.2    Any conflicts between the Protocol and this Agreement are controlled by
this Agreement.

7.3     This Agreement shall be construed and enforced in accordance with the
laws of the State of Texas.

7.4     This Agreement anticipates educational training and may involve health
science postgraduates and other students of the Institution.

<PAGE>

     IN WITNESS WHEREOF, Institution and Sponsor hereby enter into this
Agreement, effective as of the date first set forth above, and execute two (2)
original counterparts.

SPONSOR                              THE UNIVERSITY OF TEXAS
                                     M.D. ANDERSON CANCER CENTER

By: /s/ Richard Cole                 By:/s/
                                     Leonard A. Zwelling, M.D., M.B.A
Title: CEO                           Vice President for Research Administration

Date: May 15, 2002                   Date: May 15, 2002

I ACKNOWLEDGE THAT I HAVE READ THIS AGREEMENT IN ITS ENTIRETY AND THAT I SHALL
USE REASONABLE EFFORTS TO UPHOLD MY INDIVIDUAL OBLIGATIONS AND RESPONSIBILITIES
SET FORTH HEREIN:

By: /s/ Zeev Extrov

    Principal Investigator

By: /s/ Moseh Talzez

    Chair

By: Waun Ki Hong

    Head, Division of Cancer Medicine

Make Payment to:
The University of Texas
M.D. Anderson Cancer Center
Attn: Manager, Grants & Contracts Accounting
P.O. Box 297402
Houston, TX 77297
Tax I.D. 74 6001118 A1

<PAGE>

                                   APPENDIX I

NASA CASE NUMBER            TITLE                                PATENT STATUS
------------------          -----                               --------------

MSC-21560-1    "THREE-DIMENSIONAL CO-CULTURE PROCESS"     U.S. PAT NO. 5,153,132
                                                          ISSUED OCTOBER 6, 1992

ABSTRACT
--------

Laboratory process provides environmental conditions favoring simultaneous
growth of cocultures of mammalian cells of more than one type. Cultures become
three-dimensional tissue-like assemblies serving as organoid models of
differentiation of cells. Process used, for example, to study growth of human
colon cancers, starting from mixtures of normal colonic fibroblasts and
partially differentiated colon adenocarcinoma cells.

MSC-21294-2    "METHOD FOR CULTURING MAMMALIAN CELLS      U.S. PAT NO. 5,153,133
                IN A HORIZONTALLY ROTATED BIOREACTOR"     ISSUED OCTOBER 6, 1992

ABSTRACT

A bio-reactor system where cell growth microcarrier beads are suspended in a
zero head space fluid medium by rotation about a horizontal axis and where the
fluid is continuously oxygenated from a tubular membrane which rotates on a
shaft together with rotation of the culture vessel. The oxygen is continuously
throughput through the membrane and disbursed into the fluid medium along the
length of the membrane.

MSC-21559-1    "THREE-DIMENSIONAL CELL TO TISSUE          U.S. PAT NO. 5,155,034
                ASSEMBLY PROCESS"                        ISSUED OCTOBER 13, 1992

                                    ABSTRACT

The present invention relates to a 3-dimensional cell to tissue and maintenance
process, more particularly to methods of culturing cells in a culture
environment, either in space or in a gravity field, with minimum fluid shear
stress, freedom for 3-dimensional spatial orientation of the suspended particles
and localization of particles with differing or similar sedimentation properties
in a similar spatial region.

MSC-21293-2    "METHOD FOR CULTURING MAMMALIAN CELLS      U.S. PAT.NO. 5,155,035
                PERFUSED BIOREACTOR                      ISSUED OCTOBER 13, 1992

                                    ABSTRACT

A bio-reactor system wherein a tubular housing contains an internal circularly
disposed set of blade members and a central tubular filter all mounted for
rotation about a common horizontal axis and each having independent rotational
support and rotational drive mechanisms. The housing, blade members and filter
preferably are driven at a constant slow speed for placing a fluid culture
medium with discrete microbeads and cell cultures in a discrete spatial
suspension in the housing. Replacement fluid medium is symmetrically input and
fluid medium is symmetrically output from the housing where the input and the
output are part of a loop providing a constant or intermittent flow of fluid
medium in a closed loop.

<PAGE>

MSC-21560-2    "MULTI-CELLULAR THREE-DIMENSIONAL          U.S. PAT NO. 5,308,764
                LIVING MAMMALIAN TISSUE"                  ISSUED MAY 3, 1994

                                    ABSTRACT

The present invention relates to a multicellular, three-dimensional, living
mammalian tissue. The tissue is produced by a co-culture process wherein two
distinct types of mammalian cells are co-cultured in a rotating bioreactor which
is completely filled with culture media and cell attachment substrates. As the
size of the tissue assemblies formed on the attachment substrates changes, the
rotation of the bioreactor is adjusted accordingly.

MSC-21984-1     "CULTURED NORMAL MAMMALIAN TISSUE         U.S. PAT NO. 5,496,722
                 AND PROCESS"                             ISSUED MARCH 5, 1996

                                    ABSTRACT

Normal mammalian tissue and the culturing process has been developed for the
three groups of organ, structural and blood tissue. The cells are grown in vitro
under microgravity culture conditions and form three dimensional cells
aggregates with normal cell function. The microgravity culture conditions may be
microgravity or simulated microgravity created in a horizontal rotating wall
culture vessel.

MSC-21560-3    "MULTI-CELLULAR, THREE-DIMENSIONAL         U.S. PAT NO. 5,627,021
                LIVING MAMMALIAN TISSUE"                  ISSUED MAY 6, 1997

ABSTRACT

The process of the present invention relates to a three dimensional co-culture
process.

MSC-21984-2     "MEDIA COMPOSITIONS FOR THREE-            U.S. PAT NO. 5,846,807
                 DIMENSIONAL MAMMALIAN TISSUE            ISSUED DECEMBER 8, 1998
                 GROWTH UNDER
                                    ABSTRACT

Normal mammalian tissue and the culturing process has been developed for the
three groups of organ, structural and blood tissue. The cells are grown in vitro
under microgravity culture conditions and form three dimensional cells
aggregates with normal cell function. The microgravity culture conditions may be
microgravity or simulated microgravity created in a horizontal rotating wall
culture vessel.

MSC-21984-3    "PRODUCTION OF NORMAL MAMMALIAN ORGAN      U.S. PAT NO. 5,858,783
                CULTURE USING A MEDIUM CONTAINING        ISSUED JANUARY 12, 1999
                MEM- ALPHA, LEIBOVITZ L-15, GLUCOSE
                GALACTOSE FRUCTOSE

<PAGE>

                                    ABSTRACT

Normal mammalian tissue and the culturing process has been developed for the
three groups of organ, structural and blood tissue. The cells are grown in vitro
under micro-gravity culture conditions and form three dimensional cells
aggregates with normal cell function. The microgravity culture conditions may be
microgravity or simulated micro-gravity created in a horizontal rotating wall
culture vessel. The medium used for culturing the cells, especially a mixture of
epithelial and mesenchymal cells contains a mixture of Mem-alpha and Leibovits
L15 supplemented with glucose, galactose and fructose.

MSC-22119-1    "CULTURED HIGH-FIDELITY                   U.S. PAT NO. 5,851,816
                THREE DIMENSIONAL HUMAN UROGENITAL        ISSUED DEC. 22, 1998
                TRACT CARCINOMAS AND PROCESS"

                                    ABSTRACT

Artificial high-fidelity three-dimensional human urogenital tract carcinomas are
propagated under in vitro-microgravity conditions from carcinoma cells.
Artificial high-fidelity three-dimensional human urogenital tract carcinomas are
also propagated from a coculture of normal urogenital tract cells inoculated
with carcinoma cells. The microgravity culture conditions may be microgravity or
simulated microgravity created in a horizontal rotating wall culture vessel.

MSC-22122      "HORIZONTAL ROTATING-WALL VESSEL           U.S. PAT NO. 6,117,674
                PROPAGATION IN VITRO HUMAN TISSUE         ISSUED SEPT. 12, 2000
                MODELS"

                                    ABSTRACT

A process for propagating a pathogen in a three-dimensional tissue mass cultured
at microgravity conditions in a culture vessel containing culture media and a
culture matrix is provided. The three-dimensional tissue mass is inoculated with
a pathogen and pathogen replication in the cells of the tissue mass achieved.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00045-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00045-of-00352.parquet"}]]